153 related articles for article (PubMed ID: 32801136)
1. Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials.
Deng H; Zhang BL; Tong JD; Yang XH; Jin HM
J Rheumatol; 2021 Jul; 48(7):1082-1089. PubMed ID: 32801136
[TBL] [Abstract][Full Text] [Related]
2. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Zhao L; Cao L; Zhao TY; Yang X; Zhu XX; Zou HJ; Wan WG; Xue Y
Chin Med J (Engl); 2020 Apr; 133(8):982-993. PubMed ID: 32106120
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis.
Cuenca JA; Balda J; Palacio A; Young L; Pillinger MH; Tamariz L
Int J Rheumatol; 2019; 2019():1076189. PubMed ID: 30863448
[TBL] [Abstract][Full Text] [Related]
8. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
[TBL] [Abstract][Full Text] [Related]
9. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
10. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L; Wang B; Pan Y; Lu Y; Cheng R
Clin Cardiol; 2021 Jul; 44(7):907-916. PubMed ID: 34013998
[TBL] [Abstract][Full Text] [Related]
12. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
Ghang BZ; Lee JS; Choi J; Kim J; Yoo B
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35732345
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.
Ghang B; Ahn SM; Kim J; Kim YG; Lee CK; Yoo B
Rheumatology (Oxford); 2020 Jun; 59(6):1439-1440. PubMed ID: 31748801
[No Abstract] [Full Text] [Related]
18. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
Jansen TLTA; Janssen M
Clin Rheumatol; 2019 Jan; 38(1):263-265. PubMed ID: 30542798
[TBL] [Abstract][Full Text] [Related]
19. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
